<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905121</url>
  </required_header>
  <id_info>
    <org_study_id>BPL-PSILO-101</org_study_id>
    <nct_id>NCT04905121</nct_id>
  </id_info>
  <brief_title>Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)</brief_title>
  <official_title>An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beckley Psytech Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beckley Psytech Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory open-label phase 1b, ascending dose study is to evaluate the effects of&#xD;
      psilocybin on cognition in patients with Chronic Short-Lasting Unilateral Neuralgiform&#xD;
      Headache Attacks (SUNHA)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims to:&#xD;
&#xD;
      Determine the safety and tolerability of psilocybin when administered to patients with&#xD;
      chronic SUNHA&#xD;
&#xD;
      Determine the effects of psilocybin on cognition when administered to patients with chronic&#xD;
      SUNHA&#xD;
&#xD;
      Explore the change in frequency, duration, and intensity of headache attacks with escalating&#xD;
      doses of psilocybin in patients with chronic SUNHA&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>An exploratory open-label phase 1b, ascending dose study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with treatment emergent AEs (TEAES)</measure>
    <time_frame>From first dose administered through to the follow up visit, approximately 16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related changes in Paired Associates Learning (PAL) scores and evaluation of dose response</measure>
    <time_frame>From first dose administered until the las dose administered, approximately 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related changes in Spatial Working Memory (SWM) scores and evaluation of dose response</measure>
    <time_frame>From first dose administered until the las dose administered, approximately 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related changes in Reaction Time Index (RTI) scores and evaluation of dose response</measure>
    <time_frame>From first dose administered until the las dose administered, approximately 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related changes in Rapid Visual Information Processing (RVP) scores and evaluation of dose response</measure>
    <time_frame>From first dose administered until the las dose administered, approximately 11 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in frequency of headache attacks</measure>
    <time_frame>From screening until the follow up visit, approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in duration of headache attacks</measure>
    <time_frame>From screening until the follow up visit, approximately 30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in intensity of headache attacks</measure>
    <time_frame>From screening until the follow up visit, approximately 30 days</time_frame>
    <description>Patients will complete a diary on a daily basis and capture the intensity of their headaches by assigning a score out of 10 where 0 is pain free and 10 is excruciating pain</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Short Lasting Unilateral Neuralgiform Headache Attacks</condition>
  <arm_group>
    <arm_group_label>Psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>Psilocybin will be provided in form of dry filled capsules and administered orally in three ascending doses</description>
    <arm_group_label>Psilocybin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        * Diagnosed with chronic SUNHA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        * Other comorbidities&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr. Giorgio Lambru</last_name>
    <phone>0207188 3237</phone>
    <email>g.lambru@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr. Manjit Matharu</last_name>
    <email>headache@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Rucker, MRCPsych</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psilocybin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the UK GDPR, individual participant data will not be shared publicly. Group data will be presented in publication after study completion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

